March 21, 2026 a 07:43 am
PFE: Fundamental Ratio Analysis - Pfizer Inc.
Pfizer Inc., recognized for its strong position in the biopharmaceutical sector, continues to innovate with groundbreaking treatments and vaccines. The stock maintains a balanced risk-reward profile in a turbulent market environment. Investors should consider its steady earnings potential and established collaborations.
Fundamental Rating
Pfizer's fundamental health appears solid, with particular strengths in returns and cash flow, though its debt management could use some improvement.
| Category | Score | Visualization |
|---|---|---|
| Overall | 3 | |
| Discounted Cash Flow | 4 | |
| Return on Equity | 4 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 3 |
Historical Rating
The ratings show consistency over time, reflecting stable financial performance despite market changes.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-20 | 3 | 4 | 4 | 4 | 1 | 2 | 3 |
| Previous | 0 | 4 | 4 | 4 | 1 | 2 | 3 |
Analyst Price Targets
Analysts' estimates suggest a balanced view with modest price fluctuations expected in the future.
| High | Low | Median | Consensus |
|---|---|---|---|
| 35 | 24 | 27 | 27.5 |
Analyst Sentiment
Current analyst sentiment indicates a predominantly neutral to positive outlook with some holding recommendations.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 15 | |
| Hold | 22 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Pfizer Inc. stands as a strong entity in the healthcare sector, with steady performance indicators despite market volatility. The company benefits from a robust product pipeline and strategic partnerships, although high competition and regulatory challenges present risks. Investors may find value in its consistent returns and commitment to innovation, balanced against its current debt profile. The stock is predominantly seen as a 'Hold', reflecting its stable yet cautious growth outlook. Overall, Pfizer continues to offer a compelling long-term investment prospect.